Welcome to our dedicated page for Nanobiotix news (Ticker: NBTX), a resource for investors and traders seeking the latest updates and insights on Nanobiotix stock.
Nanobiotix S.A. develops nanotechnology-based therapeutic platforms for cancer and other major diseases as a late-stage clinical biotechnology company. Its news commonly centers on JNJ-1900 (NBTXR3), a hafnium oxide nanoparticle radioenhancer administered by intratumoral injection and activated by radiotherapy, including head and neck cancer and lung cancer development updates, clinical data presentations, and regulatory communications.
Company updates also cover the Nanoprimer platform for bioavailability and biodistribution, preclinical work with lipid nanoparticle-delivered therapies, collaborations with Johnson & Johnson, Janssen and MD Anderson, periodic operating and financial results, and recurring disclosures of share capital and voting rights for its Euronext Paris and Nasdaq-listed securities.
Summary not available.
Nanobiotix has announced significant milestones regarding its pivotal Phase III study, NANORAY-312, for advanced head and neck cancer, aiming for US site activation in Q3 2022. The company has received FDA feedback on a Phase III protocol for NBTXR3 in combination with anti-PD-1 therapy, with submission targeted for Q1 2023. As of March 31, 2022, Nanobiotix reported a cash position of €70.6 million. The company is implementing strategies to reduce operating expenses and has established an equity financing line to extend its financial runway into Q4 2023, while also exploring debt restructuring options.
Nanobiotix (Euronext: NANO – NASDAQ: NBTX), a late-stage biotechnology company focused on cancer treatment, announced participation in the Jefferies Healthcare Conference on June 8, 2022, at 1:00 PM ET. Laurent Levy, co-founder and chairman, and Bart Van Rhijn, CFO, will present at the event. A live webcast and replay will be available on the company's website. Founded in 2003 and headquartered in Paris, Nanobiotix specializes in physics-based therapeutic innovations.
NANOBIOTIX, a clinical-stage biotechnology company, announced participation in two upcoming conferences: the UBS Global Healthcare Conference on May 23, 2022, at 10:45 AM ET in New York, and the H.C. Wainwright Global Investment Conference on May 25, 2022, at 8:30 AM ET, available virtually and in Miami, Florida. Live webcasts will be accessible via the company’s events page, with replays available within 48 hours. NANOBIOTIX focuses on innovative cancer treatments, particularly their lead product, NBTXR3.
Nanobiotix (Nasdaq: NBTX) announced its total number of voting rights as of April 30, 2022. The company has 34,875,872 shares outstanding. The total voting rights, gross, stand at 36,392,064, while the net voting rights count is 36,371,073. These figures are disclosed in compliance with the French Commercial Code and regulations from the Autorité des Marchés Financiers.
Nanobiotix is set to announce its financial results for Q1 2022 on May 18, 2022, after the US market closes. A conference call will follow on May 19, 2022, at 8 AM EDT, where CEO Laurent Levy and CFO Bart Van Rhijn will discuss results and updates on operations. The company, known for its innovative cancer treatment NBTXR3, is advancing clinical studies, particularly in head and neck cancer. NBTXR3 has received Fast Track designation from the FDA, highlighting its potential in oncology.
Nanobiotix announced the presentation of three abstracts for its first-in-class radioenhancer NBTXR3 at the 2022 ASCO Annual Meeting from June 3-7. CEO Laurent Levy highlighted the aim to improve cancer patient outcomes by validating NBTXR3's safety and efficacy across various treatments. The accepted abstracts cover clinical trials involving head and neck cancer and rectal cancer. NBTXR3 is designed to induce significant tumor cell death when activated by radiotherapy and is currently under evaluation for several indications.
Nanobiotix announced new preclinical data at the 2022 American Association of Cancer Research meeting, showcasing the effectiveness of NBTXR3 in combination with anti-PD-1, anti-LAG-3, and anti-TIGIT therapies. The study indicated that this combination therapy significantly enhanced immune activation, longevity in anti-cancer memory, and overall survival in mice. This suggests potential effectiveness against metastatic cancers, indicating a promising avenue for future clinical applications.
Nanobiotix filed its universal registration document and Annual Report on Form 20-F for the financial year ended December 31, 2021, with the AMF and SEC, respectively. These documents include the annual financial report, corporate governance management report, auditor's reports, and details about the company’s share buyback program. Notably, Nanobiotix's NBTXR3, a novel oncology product, is showing early efficacy signs in clinical trials for advanced head and neck cancer. The company plans future financial updates on May 10, June 21, September 7, and November 9, 2022.
Nanobiotix, listed on Euronext Paris and Nasdaq (NBTX), has reported its outstanding shares as of March 31, 2022, at 34,875,872. The total voting rights stood at 36,317,823 gross and 36,304,866 net. The company is pioneering physics-based therapeutic approaches, notably in oncology with its lead product, NBTXR3, which has secured market authorization in Europe for soft tissue sarcoma treatment under the brand name Hensify®.
For further details, visit www.nanobiotix.com.